Conducting cost-effectiveness analyses of type 2 diabetes in low- and middle-income countries: Can locally generated observational study data overcome methodological limitations?

Sei-Hyun Baik, Antônio Roberto Chacra, Li Yuxiu, Jeremy White, Serdar Güler, Zafar A. Latif

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In low- and middle-income countries, the high personal and economic burden of type 2 diabetes is further compounded by inadequate resources for diabetes care when compared with high-income countries. Health technology assessments (HTAs) aim to inform policy decision makers in their efforts to achieve more effective allocation of resources by providing evidence-based input on new technologies. Within the hierarchy of evidence, randomized controlled trials (RCTs) remain the 'gold standard' used to inform HTAs, but are limited by poor external validity (ie, generalizability to real-world populations). Unlike RCTs, observational studies are able to enrol broader patient populations, but their design renders such studies vulnerable to confounding factors and selection bias. However, it is increasingly recognized that observational studies can complement RCTs by supporting and extending efficacy findings from RCTs to real-world clinical practice, particularly across geographical populations. They can also provide locally relevant baseline and disease natural history data to populate health economic models. Thus, observational data are likely to be of considerable informative value to policy makers in developing countries reaching decisions on diabetes care within an environment of scarce resources.

Original languageEnglish
Pages (from-to)17-22
Number of pages6
JournalDiabetes Research and Clinical Practice
Volume88
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 2010 May 1

Fingerprint

Type 2 Diabetes Mellitus
Cost-Benefit Analysis
Observational Studies
Randomized Controlled Trials
Biomedical Technology Assessment
Administrative Personnel
Population
Economic Models
Resource Allocation
Selection Bias
Natural History
Developing Countries
Economics
Technology
Health

Keywords

  • Cost-effectiveness analyses
  • Health economic models
  • Observational studies
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Conducting cost-effectiveness analyses of type 2 diabetes in low- and middle-income countries : Can locally generated observational study data overcome methodological limitations? / Baik, Sei-Hyun; Chacra, Antônio Roberto; Yuxiu, Li; White, Jeremy; Güler, Serdar; Latif, Zafar A.

In: Diabetes Research and Clinical Practice, Vol. 88, No. SUPPL. 1, 01.05.2010, p. 17-22.

Research output: Contribution to journalArticle

@article{3cf2629750894d91a733701238b3acf9,
title = "Conducting cost-effectiveness analyses of type 2 diabetes in low- and middle-income countries: Can locally generated observational study data overcome methodological limitations?",
abstract = "In low- and middle-income countries, the high personal and economic burden of type 2 diabetes is further compounded by inadequate resources for diabetes care when compared with high-income countries. Health technology assessments (HTAs) aim to inform policy decision makers in their efforts to achieve more effective allocation of resources by providing evidence-based input on new technologies. Within the hierarchy of evidence, randomized controlled trials (RCTs) remain the 'gold standard' used to inform HTAs, but are limited by poor external validity (ie, generalizability to real-world populations). Unlike RCTs, observational studies are able to enrol broader patient populations, but their design renders such studies vulnerable to confounding factors and selection bias. However, it is increasingly recognized that observational studies can complement RCTs by supporting and extending efficacy findings from RCTs to real-world clinical practice, particularly across geographical populations. They can also provide locally relevant baseline and disease natural history data to populate health economic models. Thus, observational data are likely to be of considerable informative value to policy makers in developing countries reaching decisions on diabetes care within an environment of scarce resources.",
keywords = "Cost-effectiveness analyses, Health economic models, Observational studies, Type 2 diabetes",
author = "Sei-Hyun Baik and Chacra, {Ant{\^o}nio Roberto} and Li Yuxiu and Jeremy White and Serdar G{\"u}ler and Latif, {Zafar A.}",
year = "2010",
month = "5",
day = "1",
doi = "10.1016/S0168-8227(10)70004-8",
language = "English",
volume = "88",
pages = "17--22",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Conducting cost-effectiveness analyses of type 2 diabetes in low- and middle-income countries

T2 - Can locally generated observational study data overcome methodological limitations?

AU - Baik, Sei-Hyun

AU - Chacra, Antônio Roberto

AU - Yuxiu, Li

AU - White, Jeremy

AU - Güler, Serdar

AU - Latif, Zafar A.

PY - 2010/5/1

Y1 - 2010/5/1

N2 - In low- and middle-income countries, the high personal and economic burden of type 2 diabetes is further compounded by inadequate resources for diabetes care when compared with high-income countries. Health technology assessments (HTAs) aim to inform policy decision makers in their efforts to achieve more effective allocation of resources by providing evidence-based input on new technologies. Within the hierarchy of evidence, randomized controlled trials (RCTs) remain the 'gold standard' used to inform HTAs, but are limited by poor external validity (ie, generalizability to real-world populations). Unlike RCTs, observational studies are able to enrol broader patient populations, but their design renders such studies vulnerable to confounding factors and selection bias. However, it is increasingly recognized that observational studies can complement RCTs by supporting and extending efficacy findings from RCTs to real-world clinical practice, particularly across geographical populations. They can also provide locally relevant baseline and disease natural history data to populate health economic models. Thus, observational data are likely to be of considerable informative value to policy makers in developing countries reaching decisions on diabetes care within an environment of scarce resources.

AB - In low- and middle-income countries, the high personal and economic burden of type 2 diabetes is further compounded by inadequate resources for diabetes care when compared with high-income countries. Health technology assessments (HTAs) aim to inform policy decision makers in their efforts to achieve more effective allocation of resources by providing evidence-based input on new technologies. Within the hierarchy of evidence, randomized controlled trials (RCTs) remain the 'gold standard' used to inform HTAs, but are limited by poor external validity (ie, generalizability to real-world populations). Unlike RCTs, observational studies are able to enrol broader patient populations, but their design renders such studies vulnerable to confounding factors and selection bias. However, it is increasingly recognized that observational studies can complement RCTs by supporting and extending efficacy findings from RCTs to real-world clinical practice, particularly across geographical populations. They can also provide locally relevant baseline and disease natural history data to populate health economic models. Thus, observational data are likely to be of considerable informative value to policy makers in developing countries reaching decisions on diabetes care within an environment of scarce resources.

KW - Cost-effectiveness analyses

KW - Health economic models

KW - Observational studies

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=77952733674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952733674&partnerID=8YFLogxK

U2 - 10.1016/S0168-8227(10)70004-8

DO - 10.1016/S0168-8227(10)70004-8

M3 - Article

C2 - 20466164

AN - SCOPUS:77952733674

VL - 88

SP - 17

EP - 22

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - SUPPL. 1

ER -